Skip to main content

Effect of thiamine administration on metabolic profile, cytokines and inflammatory markers in drug-naïve patients with type 2 diabetes



To evaluate the effect of thiamine administration on metabolic profile, cytokines and inflammatory markers in drug-naïve patients with type 2 diabetes mellitus (T2DM).


A randomized, double-blind, placebo-controlled, pilot-scale clinical trial was carried out in 24 patients with T2DM. Twelve subjects received thiamine orally (150 mg), once daily during a fasting state for 1 month. An additional 12 patients (control group) were given placebo for the same period of time. Before and after the intervention, fasting glucose, A1C, creatinine, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, very low-density lipoprotein, high-sensitive C-reactive protein, interleukin 6, tumor necrosis factor-alpha, leptin and adiponectin levels were estimated. Wilcoxon’s signed-rank and Mann–Whitney U test were used for statistical analyses.


There were significant decreases in glucose (6.7 ± 1.0 mmol/l vs. 6.0 ± 1.0 mmol/l, p = 0.024) before and after the intervention, respectively, and leptin concentrations (32.9 ± 13.3 ng/ml vs. 26.9 ± 12.8 ng/ml, p = 0.027) before and after the intervention, respectively, with thiamine administration. There were no changes with the rest of the measurements.


Thiamine administration for 1 month decreased glucose and leptin concentrations in drug-naïve patients with T2DM.

This is a preview of subscription content, access via your institution.


  1. Blonde L (2007) State of diabetes care in the United States. Am J Manag Care 13(Suppl 2):S36–S40

    Google Scholar 

  2. King GL (2008) The role of inflammatory cytokines in diabetes and its complications. J Periodontol 79(Suppl 8):1527–1534

    Article  CAS  Google Scholar 

  3. Beltramo E, Berrone E, Tarallo S, Porta M (2008) Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications. Acta Diabetol 45:131–141

    Article  CAS  Google Scholar 

  4. Babaei-Jadidi R, Karachalias N, Kupich C, Ahmed N, Thornalley PJ (2004) High-dose thiamine therapy counters dyslipidaemia in streptozotocin-induced diabetic rats. Diabetologia 47:2235–2246

    Article  CAS  Google Scholar 

  5. Thornalley PJ, Babaei-Jadidi R, Al Ali H, Rabbani N, Antonysunil A, Larkin J, Ahmed A, Rayman G, Bodmer CW (2007) High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 50:2164–2170

    Article  CAS  Google Scholar 

  6. Thornalley PJ (2005) The potential role of thiamine (vitamin B1) in diabetic complications. Curr Diabetes Rev 1:287–298

    Article  CAS  Google Scholar 

  7. Rabbani N, Alam SS, Riaz S, Larkin JR, Akhatar MW, Shafi T, Thornalley PJ (2009) High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomized, double-blind placebo-controlled pilot study. Diabetologia 52:208–212

    Article  CAS  Google Scholar 

  8. Jeyaseelan L, Rao PSS (1989) Methods of determining sample sizes in clinical trials. Indian Pediatr 26:115–121

    CAS  Google Scholar 

  9. Robles-Cervantes JA, Martínez-Abundis E, González-Ortiz M, Cárdenas-Camarena L, Hernández-Salazar E, Olvera-Ozuna R (2007) Behavior of insulin sensitivity and its relation to leptin and tumor necrosis factor-alpha in obese women undergoing liposuction: 6-month follow-up. Obes Surg 17:1242–1247

    Article  Google Scholar 

  10. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ (2003) Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52:2110–2120

    Article  CAS  Google Scholar 

  11. Marchetti V, Menghini R, Rizza S, Vivanti A, Feccia T, Lauro D, Fukamizu A, Lauro R, Federici M (2006) Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling. Diabetes 55:2231–2237

    Article  CAS  Google Scholar 

  12. Martin SS, Qasim A, Reilly MP (2008) Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol 52:1201–1210

    Article  CAS  Google Scholar 

  13. Schreeb KH, Freudenthaler S, Vormfelde SV, Gundert-Remy U, Gleiter CH (1997) Comparative bioavailability of two vitamin B1 preparations: benfotiamine and thiamine mononitrate. Eur J Clin Pharmacol 52:319–320

    CAS  Google Scholar 

  14. Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, Götting C, Kleesiek K, Mueller-Roesel M, Koschinsky T, Uribarri J, Vlassara H, Tschoepe D (2006) Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 29:2064–2071

    Article  CAS  Google Scholar 

  15. Du X, Edelstein D, Brownlee M (2008) Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes. Diabetologia 51:1930–1932

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Manuel González-Ortiz.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

González-Ortiz, M., Martínez-Abundis, E., Robles-Cervantes, J.A. et al. Effect of thiamine administration on metabolic profile, cytokines and inflammatory markers in drug-naïve patients with type 2 diabetes. Eur J Nutr 50, 145–149 (2011).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • Thiamine
  • Metabolic profile
  • Cytokines
  • Inflammatory markers
  • Type 2 diabetes